TMEM9B

Across TCGA pan-cancer cohorts, TMEM9B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM9B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM9B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM9B expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where TMEM9B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.803	0.524	<.001	64	view →
COAD	DFS	Median	II,III,IV	1.000	0.928	.041	12	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
LSCC	DFS	Quartile	All	0.810	1.000	.022	3	view →
CCRCC	OS	Median	II,III,IV	0.651	0.855	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM9B–HNSC (DFS)

Open the HNSC breakdown →